| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| References | |
|---|---|
| Additional Infomation |
Wee1 Inhibitor is any agent that inhibits Wee1-like protein kinase (Wee1; Wee1A kinase; WEE1hu).
|
| Molecular Formula |
C20H11N2O3CL
|
|---|---|
| Molecular Weight |
362.76594
|
| Exact Mass |
362.046
|
| CAS # |
622855-37-2
|
| PubChem CID |
10384072
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
4.241
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
614
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DPEXRCOBPACFOO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H11ClN2O3/c21-13-4-2-1-3-10(13)11-8-15-16(18-17(11)19(25)23-20(18)26)12-7-9(24)5-6-14(12)22-15/h1-8,22,24H,(H,23,25,26)
|
| Chemical Name |
4-(2-chlorophenyl)-9-hydroxy-6H-pyrrolo[3,4-c]carbazole-1,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~275.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7566 mL | 13.7828 mL | 27.5657 mL | |
| 5 mM | 0.5513 mL | 2.7566 mL | 5.5131 mL | |
| 10 mM | 0.2757 mL | 1.3783 mL | 2.7566 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05368506 | Withdrawn | Drug: Wee1 Inhibitor ZN-c3 | Advanced Fallopian Tube Carcinoma Advanced Ovarian Carcinoma Advanced Primary Peritoneal Carcinoma Anatomic Stage IV Breast Cancer AJCC v8 |
OHSU Knight Cancer Institute | 2023-07-30 | Early Phase 1 |
| NCT02791919 | Withdrawn | Drug: Cytarabine Biological: Filgrastim Drug: Fludarabine Phosphate |
CNS 2a CNS 2b CNS 2c CNS1 |
National Cancer Institute (NCI) | 2017-05-25 | Phase 1 |
| NCT02196168 | Terminated | Drug: Cisplatin Other: Laboratory Biomarker Analysis Other: Pharmacological Study |
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Laryngeal Verrucous Carcinoma Recurrent Lip and Oral Cavity Squamous Cell Carcinoma |
National Cancer Institute (NCI) | 2014-03 | Phase 2 |
| NCT02101775 | Active, not recruiting | Drug: Adavosertib Drug: Gemcitabine Hydrochloride Other: Laboratory Biomarker Analysis |
Ovarian Brenner Tumor Ovarian Carcinosarcoma Ovarian Clear Cell Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma |
National Cancer Institute (NCI) | 2014-07-21 | Phase 2 |
| NCT02381548 | Terminated | Drug: Adavosertib Drug: Belinostat Other: Laboratory Biomarker Analysis Other: Pharmacological Study |
Acute Myeloid Leukemia Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome |
National Cancer Institute (NCI) | 2015-08-18 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
